These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 15102666)
1. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Liu KJ; Wang CC; Chen LT; Cheng AL; Lin DT; Wu YC; Yu WL; Hung YM; Yang HY; Juang SH; Whang-Peng J Clin Cancer Res; 2004 Apr; 10(8):2645-51. PubMed ID: 15102666 [TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen. Itoh T; Ueda Y; Kawashima I; Nukaya I; Fujiwara H; Fuji N; Yamashita T; Yoshimura T; Okugawa K; Iwasaki T; Ideno M; Takesako K; Mitsuhashi M; Orita K; Yamagishi H Cancer Immunol Immunother; 2002 Apr; 51(2):99-106. PubMed ID: 11904734 [TBL] [Abstract][Full Text] [Related]
3. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Weihrauch MR; Ansén S; Jurkiewicz E; Geisen C; Xia Z; Anderson KS; Gracien E; Schmidt M; Wittig B; Diehl V; Wolf J; Bohlen H; Nadler LM Clin Cancer Res; 2005 Aug; 11(16):5993-6001. PubMed ID: 16115944 [TBL] [Abstract][Full Text] [Related]
4. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. Ueda Y; Itoh T; Nukaya I; Kawashima I; Okugawa K; Yano Y; Yamamoto Y; Naitoh K; Shimizu K; Imura K; Fuji N; Fujiwara H; Ochiai T; Itoi H; Sonoyama T; Hagiwara A; Takesako K; Yamagishi H Int J Oncol; 2004 Apr; 24(4):909-17. PubMed ID: 15010829 [TBL] [Abstract][Full Text] [Related]
5. Induction of specific CTL by MAGE-3/CEA peptide-pulsed dendritic cells from HLA-A2/A24(+) gastrointestinal cancer patients. Hao X; Shao Y; Ren X; Liu H; Xu Q; Li H; Zhang P; An X; Ren B J Cancer Res Clin Oncol; 2002 Sep; 128(9):507-15. PubMed ID: 12242516 [TBL] [Abstract][Full Text] [Related]
6. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Ullenhag GJ; Frödin JE; Jeddi-Tehrani M; Lidströmer N; Strigård K; Eriksson E; Samanci A; Choudhury A; Nilsson B; Rossmann ED; Mosolits S; Mellstedt H Clin Cancer Res; 2004 May; 10(10):3273-81. PubMed ID: 15161680 [TBL] [Abstract][Full Text] [Related]
7. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414 [TBL] [Abstract][Full Text] [Related]
8. Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells. Matsuda K; Tsunoda T; Tanaka H; Umano Y; Tanimura H; Nukaya I; Takesako K; Yamaue H Cancer Immunol Immunother; 2004 Jul; 53(7):609-16. PubMed ID: 14735319 [TBL] [Abstract][Full Text] [Related]
9. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Lesterhuis WJ; De Vries IJ; Schreibelt G; Schuurhuis DH; Aarntzen EH; De Boer A; Scharenborg NM; Van De Rakt M; Hesselink EJ; Figdor CG; Adema GJ; Punt CJ Anticancer Res; 2010 Dec; 30(12):5091-7. PubMed ID: 21187495 [TBL] [Abstract][Full Text] [Related]
11. Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors. Tamir A; Basagila E; Kagahzian A; Jiao L; Jensen S; Nicholls J; Tate P; Stamp G; Farzaneh F; Harrison P; Stauss H; George AJ; Habib N; Lechler RI; Lombardi G Cancer Immunol Immunother; 2007 Dec; 56(12):2003-16. PubMed ID: 17333181 [TBL] [Abstract][Full Text] [Related]
12. Streptococcal preparation OK-432 promotes the capacity of dendritic cells (DCs) to prime carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocyte responses induced with genetically modified DCs that express CEA. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Katsuda M; Miyazawa M; Iida T; Yamaue H Int J Oncol; 2008 Feb; 32(2):459-66. PubMed ID: 18202769 [TBL] [Abstract][Full Text] [Related]
13. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Morse MA; Deng Y; Coleman D; Hull S; Kitrell-Fisher E; Nair S; Schlom J; Ryback ME; Lyerly HK Clin Cancer Res; 1999 Jun; 5(6):1331-8. PubMed ID: 10389916 [TBL] [Abstract][Full Text] [Related]
14. A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment. Liu KJ; Chao TY; Chang JY; Cheng AL; Ch'ang HJ; Kao WY; Wu YC; Yu WL; Chung TR; Whang-Peng J J Biomed Sci; 2016 Aug; 23(1):64. PubMed ID: 27558635 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of cancer. Generation of CEA specific CTL using CEA peptide pulsed dendritic cells. Alters SE; Gadea JR; Philip R Adv Exp Med Biol; 1997; 417():519-24. PubMed ID: 9286413 [TBL] [Abstract][Full Text] [Related]
16. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Babatz J; Röllig C; Löbel B; Folprecht G; Haack M; Günther H; Köhne CH; Ehninger G; Schmitz M; Bornhäuser M Cancer Immunol Immunother; 2006 Mar; 55(3):268-76. PubMed ID: 16034561 [TBL] [Abstract][Full Text] [Related]
17. Novel system for generating cytotoxic effector lymphocytes using carcinoembryonic antigen (CEA) peptide and cultured dendritic cells. Ohta K; Yamaguchi Y; Shimizu K; Miyahara E; Toge T Anticancer Res; 2002; 22(5):2597-606. PubMed ID: 12529970 [TBL] [Abstract][Full Text] [Related]
18. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Kono K; Takahashi A; Sugai H; Fujii H; Choudhury AR; Kiessling R; Matsumoto Y Clin Cancer Res; 2002 Nov; 8(11):3394-400. PubMed ID: 12429626 [TBL] [Abstract][Full Text] [Related]
19. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612 [TBL] [Abstract][Full Text] [Related]
20. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma. Chang GC; Lan HC; Juang SH; Wu YC; Lee HC; Hung YM; Yang HY; Whang-Peng J; Liu KJ Cancer; 2005 Feb; 103(4):763-71. PubMed ID: 15637694 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]